AccessibilityHelpAbout Us
Microbix Biosystems logo

Microbix Biosystems(TSX) MBX

Market CapCA$42.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-48%
5 Year-49%
1 Year+22%
1 Month+5%
CA$0.30
-3.23%
-0.01Today
Microbix Biosystems last closing stock price
MetricPriceDate
Last closeCAD 0.302026-09-18
Microbix Biosystems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.23%CAD 0.312026-09-11
1 month+5.26%CAD 0.292026-08-19
3 month-1.64%CAD 0.312026-06-19
Year to date+30.43%CAD 0.232025-12-31
1 year+22.45%CAD 0.252025-09-18
3 year+0%CAD 0.302023-09-19
5 year-49.15%CAD 0.592021-09-17
Since inception-48.33%CAD 0.601992-10-01

Microbix Biosystems Financials at a Glance

Market Cap

CA$42.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$15.40M

Net Income (TTM)

-CA$4.88M

EPS (TTM)

-CA$0.04

P/E Ratio

-8.81

Dividend

CA$0.00

Beta (Volatility)

0.34 (Low)

Price

CA$0.30

Volume

28,500

Open

CA$0.31

Previous Close

CA$0.30

Daily Range

CA$0.29 - CA$0.31

52-Week Range

CA$0.21 - CA$0.33

Estimated Earnings Date

Dec 17, 2026

MBX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Microbix Biosystems

Microbix Biosystems Inc. is a life science enterprise focused on advancing human health through innovative biological and technological products. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in producing essential biological reagents for the diagnostic industry.

Products and Services
  • Biological reagents for immunoassays
  • Quality Assessment and Proficiency (QAP) products for clinical laboratories
  • Proprietary offerings like DxTM and Kinlytic Urokinase
Growth Outlook
  • Revenue increased to CAD 4.06 million in Q3 2026
  • Gross profit margin improved to 53.9% in Q3 2026
  • Strong demand for QAP products supports future growth
Financial Highlights
  • Trailing twelve-month revenue of CAD 12.5 million
  • Current ratio of 6.89 indicates strong liquidity
  • Net income of CAD -806,762 in Q3 2026 reflects ongoing investment in R&D
Microbix Biosystems Inc. operates in the biotechnology sector, providing critical products that support diagnostic testing and laboratory operations. The company has shown resilience with a notable increase in revenue and gross profit margin in recent quarters, indicating a positive trend in operational efficiency. The current ratio suggests a robust liquidity position, allowing for continued investment in research and development. Despite recent net losses, the focus on innovative products positions Microbix for potential growth in the expanding healthcare market.
AI Generated • Sep 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Cameron L. Groome

Website

microbix.com

Headquarters

Mississauga, ON L4Z 1P3, CA

MBX Financials

Key Financial Metrics (TTM)

Gross Margin

45.90%

Operating Margin

-27.69%

Net Income Margin

-31.72%

Return on Equity

-18.83%

Return on Capital

-4.56%

Return on Assets

-14.34%

Earnings Yield

-11.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$42.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

136.97M

Volume

28.50K

Avg. Volume

27.76K

Financials (TTM)

Gross Profit

CA$7.07M

Operating Income

-CA$4.26M

EBITDA

-CA$2.30M

Operating Cash Flow

-CA$3.29M

Capital Expenditure

-CA$595.17K

Free Cash Flow

-CA$3.89M

Cash & ST Invst.

CA$7.16M

Total Debt

CA$6.72M

Microbix Biosystems Performance Analysis

Microbix Biosystems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30CAD 19,076,2412.6%
20232023-09-30CAD 16,514,776-13.4%
20242024-09-30CAD 25,394,14853.8%
20252025-09-30CAD 18,585,366-26.8%
Microbix Biosystems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-307.8%
Q12025-12-3112.7%
Q22026-03-31-19.9%
Q32026-06-3020.2%
Microbix Biosystems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30CAD 0.01-51.5%
20232023-09-30CAD -0.00N/A
20242024-09-30CAD 0.03N/A
20252025-09-30CAD -0.02N/A
Microbix Biosystems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-309.4%
Q12025-12-3120.8%
Q22026-03-31-22.6%
Q32026-06-3041.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$4.06M

+16.9%

Gross Profit

CA$2.19M

+54.7%

Gross Margin

53.92%

N/A

Market Cap

CA$42.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$424.60K

N/A

Employees

100

N/A

Net Income

-CA$806.76K

+50.9%

EBITDA

-CA$186.45K

+80.8%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$7.16M

-40.8%

Total Debt

CA$6.72M

+4.9%

Accounts Receivable

CA$2.58M

+7.6%

Inventory

CA$10.56M

+19.2%

Long Term Debt

CA$6.49M

+4.8%

Short Term Debt

CA$226.60K

+6.5%

Return on Assets

-14.34%

N/A

Return on Invested Capital

-13.76%

N/A

Free Cash Flow

-CA$514.68K

+75.7%

Operating Cash Flow

-CA$466.82K

+75.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCT.TOBriaCell Therapeutics Corp.
CA$5.91-0.17%
ROMJ.VRubicon Organics Inc.
CA$0.48+5.49%
RVX.TOResverlogix Corp.
CA$0.09+0.00%
LABS.TOMediPharm Labs Corp.
CA$0.07+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About MBX

What is the current price of Microbix Biosystems?

Microbix Biosystems is trading at CA$0.30 per share.

What is the 52-week range for Microbix Biosystems?

Over the past 52 weeks, Microbix Biosystems has traded between CA$0.21 and CA$0.33.

How much debt does Microbix Biosystems have?

As of the most recent reporting period, Microbix Biosystems reported total debt of CA$6.72M.

How much cash does Microbix Biosystems have on hand?

Microbix Biosystems reported CA$7.16M in cash and cash equivalents in its most recent financial results.

What is Microbix Biosystems’s dividend yield?

Microbix Biosystems does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services